{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:28:52Z","timestamp":1793806132193,"version":"4.6.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Central nervous system (CNS) involvement following blast crisis (BC) of chronic myeloid leukemia (CML) represents a challenging complication, particularly when atypical symptoms such as progressive vision loss obscure the diagnosis and delay timely intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 65-year-old male presented with isolated CNS relapse following CML-BC, manifesting as progressive visual loss. Despite being in intramedullary complete remission and having received prophylactic intrathecal chemotherapy, the patient\u2019s atypical ocular symptom raised suspicion of CNS involvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Cerebrospinal fluid (CSF) analysis confirmed the presence of blast cells, establishing the diagnosis of CNS relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Treatment with intrathecal chemotherapy, systemic high-dose chemotherapy combined with tyrosine kinase inhibitor therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient demonstrated visual recovery and sustained disease remission at the 14-month follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case underscores the importance of clinical vigilance in patients with a history of leukemia who present with blurred vision or progressive vision impairment, as such manifestations,even in the absence of overt neurological symptoms, may be indicators of CNS relapse. Additionally, further investigation through animal models is warranted to characterize the blood-brain barrier penetrance of novel tyrosine kinase inhibitors (TKIs).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050847","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:00:55Z","timestamp":1790359255000},"page":"e50847","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Vision loss as the first manifestation of isolated cns relapse in CML blast crisis during flumatinib maintenance therapy"],"prefix":"10.1097","volume":"105","author":[{"given":"Lili","family":"Hong","sequence":"first","affiliation":[{"name":"Department of hematology, The first People\u2019s Hospital of Hangzhou Linping District, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Mu","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqian","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of hematology, The first People\u2019s Hospital of Hangzhou Linping District, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2802-7910","authenticated-orcid":false,"given":"Haifeng","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology and Transfusion, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR\u2013ABL in the pathogenesis of chronic myelogenous leukaemia.","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients.","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0145-2126(96)00054-9","article-title":"Extramedullary blast crisis in chronic myeloid leukemia.","volume":"20","author":"Specchia","year":"1996","journal-title":"Leuk Res"},{"key":"R5-20261104","first-page":"8891376","article-title":"CNS involvement in a patient with chronic myeloid leukemia.","volume":"2021","author":"Healey","year":"2021","journal-title":"Case Rep Hematol"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/s12886-026-04995-3","article-title":"Unilateral vision loss as the initial symptom of chronic myeloid leukemia with bilateral retinal infiltration: a case report.","volume":"26","author":"Chen","year":"2026","journal-title":"BMC Ophthalmol"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1445-5994.2009.01947.x","article-title":"Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate.","volume":"39","author":"Isobe","year":"2009","journal-title":"Intern Med J"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2002.03881.x","article-title":"Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid.","volume":"119","author":"Takayama","year":"2002","journal-title":"Br J Haematol"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome\u2013positive leukemia.","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1038\/bcj.2016.66","article-title":"Extramedullary sudden blast crisis in chronic-phase chronic myeloid leukemia during first-line treatment with nilotinib.","volume":"6","author":"Angelopoulou","year":"2016","journal-title":"Blood Cancer J"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1124\/dmd.110.032326","article-title":"Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients.","volume":"38","author":"Gong","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R12-20261104","doi-asserted-by":"crossref","first-page":"17588359251335905","DOI":"10.1177\/17588359251335905","article-title":"Real-world comparison of flumatinib and nilotinib as first-line therapy for patients with chronic phase chronic myeloid leukemia: a multicenter retrospective study.","volume":"17","author":"Lei","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"R13-20261104","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood.2022017035","article-title":"How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia.","volume":"141","author":"Kopmar","year":"2023","journal-title":"Blood"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.26622","article-title":"Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia.","volume":"98","author":"Paul","year":"2023","journal-title":"Am J Hematol"},{"key":"R15-20261104","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41375-024-02204-y","article-title":"Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era \u2013 analysis of the European LeukemiaNet Blast Phase Registry.","volume":"38","author":"Brioli","year":"2024","journal-title":"Leukemia"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:00:53Z","timestamp":1793804453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050847"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":15,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050847","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"2025-12-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}